Global Parkinson's Disease Therapeutics Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2018 To 2026

  • ID: 4575950
  • Report
  • Region: Global
  • Acute Market Reports
1 of 4

FEATURED COMPANIES

  • Abbvie, Inc.
  • Biogen, Inc.
  • Boehringer Ingelheim GmbH
  • F. Hoffman-La Roche
  • GlaxoSmithKline Plc.
  • H. Lundbeck A/S
  • MORE
Parkinson’s Disease Therapeutics Market - Growth, Future Prospects and Competitive Analysis, 2018 - 2026 the global Parkinson’s disease therapeutics market, was valued at US$ 2.41 Bn in 2017, and is expected to reach US$ 3.95 Bn by 2026 expanding at a CAGR of 5.6% from 2018 to 2026.

Market Insights:
Parkinson's disease is a type of progressive movement disorder, characterized by muscle rigidity, and tremors. The global Parkinson's disease therapeutics market will grow significantly over the forecast period, majorly due to presence of late stage pipeline drugs such as APL-130277, Accordion Pill, P2B-001, ND0612H etc. and rising incidence of the disease. For the purpose of the study, the global Parkinson's disease therapeutics market is categorized on the basis of drug class such as dopamine agonists, levodopa/carbidopa, anticholinergic drugs, monoamine oxidase B (MAO-B) inhibitors, catechol-O-methyltransferase (COMT) inhibitors and adenosine A2 receptor antagonist. Levodopa coupled with carbidopa remains the standard treatment of Parkinson disease which shows fewer advarese effect in short-term use. Dopamine agonists are widely accepted for treatment of PD used as alone or in combination with levodopa/carbidopa.

At present, North America leads the global PD therapeutics market owning to larger patient pool, advantage of early diagnosis, developed healthcare infrastructure and increase in prevalence of PD. It is predicted that PD therapeutics market in Asia Pacific will demonstrate lucrative growth over the forecast period because of rising prevalence of PD and improving healthcare infrastructure with developing economic condition.

Market Competition Assessment:
It is observed that, companies such as Abbvie, Inc., Biogen, Inc., Boehringer Ingelheim GmbH, F. Hoffman-La Roche, GlaxoSmithKline Plc., H. Lundbeck A/S, Impax Labs, Inc., Newron Pharmaceuticals SpA, Novartis AG, Orion Corporation, Teva Pharmaceutical Industries Ltd., UCB S.A. etc. are key players involved in R&D and manufacturing of PD therapeutics market.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Abbvie, Inc.
  • Biogen, Inc.
  • Boehringer Ingelheim GmbH
  • F. Hoffman-La Roche
  • GlaxoSmithKline Plc.
  • H. Lundbeck A/S
  • MORE
Chapter 1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I-Secondary Research
1.3.2. Phase II-Primary Research
1.3.3. Phase III-Expert Panel Review
1.3.4. Assumptions

Chapter 2. Executive Summary
2.1. Global Parkinson’s Disease Therapeutics Market Portraiture
2.1.1. Global Parkinson’s Disease Therapeutics Market, by Drug Class, 2017 (US$ Mn)
2.1.2. Global Parkinson’s Disease Therapeutics Market, by Geography, 2017 (Value %)

Chapter 3. Parkinson’s Disease Therapeutics: Market Dynamics and Outlook
3.1. Market Definition and Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Landscape
3.6.1. Competitive Landscape: Global Parkinson’s Disease Therapeutics Market, by Key Players, 2017

Chapter 4. Global Parkinson’s Disease Therapeutics Market, by Drug Class, 2016 – 2026 (US$ Mn)
4.1. Overview
4.2. Dopamine Agonists
4.3. Levodopa/ Carbidopa
4.4. Anticholinergic Drugs
4.5. Monoamine Oxidase B (MAO-B) Inhibitors
4.6. Catechol-O-Methyltransferase (COMT) Inhibitors
4.7. Adenosine A2 Receptor Antagonist
4.8. Pipeline Candidates: Overview
4.8.1. Phase III (Market estimations by 2026)
4.8.1.1. APL-130277 (Cynapsus Therapeutics-Sunovion)
4.8.1.2. Accordion Pill Carbidopa/Levodopa (Intec Pharma)
4.8.1.3. P2B-001 (Pharma Two B)
4.8.1.4. ND0612H (Neuroderm)
4.8.2. Phase II & I (Tabular Information)

Chapter 5. Global Parkinson’s Disease Therapeutics Market, by Geography, 2016 – 2026 (US$ Mn)
5.1. Overview
5.2. North America Parkinson’s Disease Therapeutics Market Analysis, 2016 – 2026 (US$ Mn)
5.2.1. North America Parkinson’s Disease Therapeutics Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.2.2. North America Parkinson’s Disease Therapeutics Market, by Country, 2016 – 2026 (US$ Mn)
5.2.2.1. U.S.
5.2.2.2. Canada
5.3. Europe Parkinson’s Disease Therapeutics Market Analysis, 2016 – 2026 (US$ Mn)
5.3.1. Europe Parkinson’s Disease Therapeutics Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.3.2. Europe Parkinson’s Disease Therapeutics Market, by Country, 2016 – 2026 (US$ Mn)
5.3.2.1. U.K.
5.3.2.2. Germany
5.3.2.3. Rest of Europe
5.4. Asia Pacific Parkinson’s Disease Therapeutics Market Analysis , 2016 – 2026 (US$ Mn)
5.4.1. Asia Pacific Parkinson’s Disease Therapeutics Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.4.2. Asia Pacific Parkinson’s Disease Therapeutics Market, by Country, 2016 – 2026 (US$ Mn)
5.4.2.1. China
5.4.2.2. Japan
5.4.2.3. Rest of APAC
5.5. Latin America Parkinson’s Disease Therapeutics Market Analysis , 2016 – 2026 (US$ Mn)
5.5.1. Latin America Parkinson’s Disease Therapeutics Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.5.2. Latin America Parkinson’s Disease Therapeutics Market, by Country, 2016 – 2026 (US$ Mn)
5.5.2.1. Brazil
5.5.2.2. Mexico
5.5.2.3. Rest of Latin America
5.6. Middle East & Africa (MEA) Parkinson’s Disease Therapeutics Market Analysis, 2016 – 2026 (US$ Mn)
5.6.1. MEA Parkinson’s Disease Therapeutics Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.6.2. MEA Parkinson’s Disease Therapeutics Market, by Country, 2016 – 2026 (US$ Mn)
5.6.2.1. GCC
5.6.2.2. Rest of MEA

Chapter 6. Company Profiles
6.1. Abbvie, Inc.
6.1.1. Business Description
6.1.2. Financial Information (Subject to data availability)
6.1.3. Product Portfolio
6.1.4. Key Developments
6.2. Biogen, Inc.
6.3. Boehringer Ingelheim GmbH
6.4. F. Hoffman-La Roche
6.5. GlaxoSmithKline Plc.
6.6. H. Lundbeck A/S
6.7. Impax Labs, Inc.
6.8. Newron Pharmaceuticals SpA
6.9. Novartis AG
6.10. Orion Corporation
6.11. Teva Pharmaceutical Industries Ltd.
6.12. UCB S.A.

List of Figures
FIG. 1 Parkinson’s Disease Therapeutics: Market Segmentation
FIG. 2 Global Parkinson’s Disease Therapeutics Market, by Drug Class, 2017 (US$ Mn)
FIG. 3 Global Parkinson’s Disease Therapeutics Market, by Geography, 2017 (Value %)
FIG. 4 Attractive Investment Proposition, by Geography, 2017
FIG. 5 Market Competition Landscape, by Key Players, 2017
FIG. 6 Global Dopamine Agonists Market, 2016 – 2026 (US$ Mn)
FIG. 7 Global Levodopa/ Carbidopa Market, 2016 – 2026 (US$ Mn)
FIG. 8 Global Anticholinergic Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 9 Global Monoamine Oxidase B (MAO-B) Inhibitors Market, 2016 – 2026 (US$ Mn)
FIG. 10 Global Catechol-O-Methyltransferase (COMT) Inhibitors Market, 2016 – 2026 (US$ Mn)
FIG. 11 Global Adenosine A2 Receptor Antagonist Market, 2016 – 2026 (US$ Mn)
FIG. 12 U.S. Parkinson’s Disease Therapeutics Market, 2016 – 2026 (US$ Mn)
FIG. 13 Canada Parkinson’s Disease Therapeutics Market, 2016 – 2026 (US$ Mn)
FIG. 14 U.K. Parkinson’s Disease Therapeutics Market, 2016 – 2026 (US$ Mn)
FIG. 15 Germany Parkinson’s Disease Therapeutics Market, 2016 – 2026 (US$ Mn)
FIG. 16 Rest of Europe Parkinson’s Disease Therapeutics Market, 2016 – 2026 (US$ Mn)
FIG. 17 Japan Parkinson’s Disease Therapeutics Market, 2016 – 2026 (US$ Mn)
FIG. 18 China Parkinson’s Disease Therapeutics Market, 2016 – 2026 (US$ Mn)
FIG. 19 Rest of Asia Pacific Parkinson’s Disease Therapeutics Market, 2016 – 2026 (US$ Mn)
FIG. 20 Brazil Parkinson’s Disease Therapeutics Market, 2016 – 2026 (US$ Mn)
FIG. 21 Mexico Parkinson’s Disease Therapeutics Market, 2016 – 2026 (US$ Mn)
FIG. 22 Rest of Latin America Parkinson’s Disease Therapeutics Market, 2016 – 2026 (US$ Mn)
FIG. 23 GCC Parkinson’s Disease Therapeutics Market, 2016 – 2026 (US$ Mn)
FIG. 24 Rest of Middle East and Africa Parkinson’s Disease Therapeutics Market, 2016 – 2026 (US$ Mn)

List of Tables
Table 1 Global Parkinson’s Disease Therapeutics Market, by Drug Class, 2016 – 2026 (US$ Mn)
Table 2 North America Parkinson’s Disease Therapeutics Market, by Drug Class, 2016 – 2026 (US$ Mn)
Table 3 North America Parkinson’s Disease Therapeutics Market, by Country, 2016 – 2026 (US$ Mn)
Table 4 Europe Parkinson’s Disease Therapeutics Market, by Drug Class, 2016 – 2026 (US$ Mn)
Table 5 Europe Parkinson’s Disease Therapeutics Market, by Country, 2016 – 2026 (US$ Mn)
Table 6 Asia Pacific Parkinson’s Disease Therapeutics Market, by Drug Class, 2016 – 2026 (US$ Mn)
Table 7 Asia Pacific Parkinson’s Disease Therapeutics Market, by Country, 2016 – 2026 (US$ Mn)
Table 8 Latin America Parkinson’s Disease Therapeutics Market, by Drug Class, 2016 – 2026 (US$ Mn)
Table 9 Latin America Parkinson’s Disease Therapeutics Market, by Country, 2016 – 2026 (US$ Mn)
Table 10 Middle East and Africa Parkinson’s Disease Therapeutics Market, by Drug Class, 2016 – 2026 (US$ Mn)
Table 11 Middle East and Africa Parkinson’s Disease Therapeutics Market, by Country, 2016 – 2026 (US$ Mn)
Table 12 Abbvie,Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 13 Biogen, Inc. : Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 14 Boehringer Ingelheim GmbH: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 15 F. Hoffman-La Roche: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 16 GlaxoSmithKline Plc. : Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 17 H. Lundbeck A/S: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 18 Impax Labs, Inc. : Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 19 Newron Pharmaceuticals SpA: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 20 Novartis AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 21 Orion Corporation: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 22 Teva Pharmaceutical Industries Ltd. : Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 23 UCB S.A. : Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Abbvie, Inc.
  • Biogen, Inc.
  • Boehringer Ingelheim GmbH
  • F. Hoffman-La Roche
  • GlaxoSmithKline Plc.
  • H. Lundbeck A/S
  • Impax Labs, Inc.
  • Newron Pharmaceuticals SpA
  • Novartis AG
  • Orion Corporation
  • Teva Pharmaceutical Industries Ltd.
  • UCB S.A.
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll